INVISTA Receives Patent for Bio-Derived Raw Materials Technology Developed Through Collaboration with Arzeda
By Business Wire News
By Business Wire News
The United States Patent and Trademark Office recently granted INVISTA a U.S. patent for bio-derived raw materials technology.
The patent is for engineered polypeptides and their related crystal structure details, which are both useful for producing bio-derived compounds such as butadiene and isoprene. INVISTA collaborated with Arzeda to develop the innovations covered by the patent, which was issued on Dec. 29, 2015.
“The work detailed in this patent provides innovative solutions to potentially increase the global supply of bio-derived chemicals,” said Bill Greenfield, president of INVISTA’s Intermediates business. “This patent is an example of INVISTA’s biotechnology research capabilities working together with Arzeda and demonstrates our commitment to developing new bio-derived processes for a range of products.”
Alexandre Zanghellini, co-founder and chief executive officer at Arzeda, said, “The issuance of this patent is yet another example of the power of combining Arzeda’s computational protein design technology Archytas™ with experimental screening to rapidly design synthetic enzymes. With INVISTA’s expertise in biotechnology and industrial scale-up, we are confident this collaboration will lead to advanced bio-processes for the production of more sustainable industrial chemicals.”
With leading brands including LYCRA®, COOLMAX®, CORDURA®, STAINMASTER® and ANTRON®, INVISTA is one of the world’s largest integrated producers of chemical intermediates, polymers and fibers. The company’s advantaged technologies for nylon, spandex and polyester are used to produce clothing, carpet, car parts and countless other everyday products. Headquartered in the United States, INVISTA operates in more than 20 countries and has about 10,000 employees. For more information, visit INVISTA.com, Facebook.com/INVISTAglobal and Twitter.com/INVISTA.
Since 2008, Arzeda has been harnessing the power of computational and synthetic biology to create new enzymes and chemical products that can compete on cost, sustainability and performance. In partnership with Fortune 500 companies and industrial leaders, the company has developed a portfolio of enzymes and specialty chemicals for polymers, advanced materials and health and nutrition products. Arzeda’s proprietary platform and validation process rapidly creates “cell factories” that can be used at industrial scales to solve problems and create opportunities that otherwise would be impossible. More information is available at www.arzeda.com and twitter.com/@ArzedaCo.
- Rogers Corporation to Participate in the CJS Securities, Inc. Sixteenth Annual “New Ideas for the New Year” Investor Conference
- New IEEE Standards Association Initiative Aims to Accelerate Immersive Shopping Experiences by Harnessing Cutting Edge Research & Innovation for 3D Body Processing Technologies